The Wall Street Journal on June 25, 2020, features Iaso Ventures as an example of the trend in healthcare VC funds leveraging disease-specific expertise to create value for entrepreneurs and maximize returns for investors.

Author Brian Gormely explains in the piece that the edge lies in more robust deal flow and better portfolio company management:

Proponents say their expertise enables them to see more of the best deals in their sector and gives them a better shot at guiding their companies to success.

The sector expertise helps in every step of the investment process:

In health care, scientific advances are leading to an explosion of new data and information across many medical fields. As a result, no one venture firm can be an expert in every disease area, said Jakob Loven, a partner with cancer-specialist Nextech Invest, an early proponent of disease-specific venture funds.

The article goes on to describe the sector focus and attributes of the Iaso Ventures fund:

Iaso Ventures formed in 2019 to invest in behavioral health and neuroscience and is raising $50 million for its debut fund, with a hard cap of $100 million, said Managing Partner Wasim Malik, formerly chief digital strategist for pharmaceutical company Roivant Sciences.